6 results on '"Blaine R. Roberts"'
Search Results
2. Quantitative Phosphoproteomics Reveals Extensive Protein Phosphorylation Dysregulation in the Cerebral Cortex of Huntington’s Disease Mice Prior to Onset of Symptoms
- Author
-
Isaline Mees, Harvey Tran, Anne Roberts, Larissa Lago, Shanshan Li, Blaine R. Roberts, Anthony J. Hannan, and Thibault Renoir
- Subjects
Cerebral Cortex ,Disease Models, Animal ,Huntingtin Protein ,Mice ,Cellular and Molecular Neuroscience ,Huntington Disease ,Neurology ,Neuroscience (miscellaneous) ,Animals ,Mice, Transgenic ,Phosphorylation ,Peptides ,Phosphoproteins - Abstract
Protein phosphorylation plays a role in many important cellular functions such as cellular plasticity, gene expression, and intracellular trafficking. All of these are dysregulated in Huntington's disease (HD), a devastating neurodegenerative disorder caused by an expanded CAG repeat in exon 1 of the huntingtin gene. However, no studies have yet found protein phosphorylation differences in preclinical HD mouse models. Our current study investigated changes occurring in the cortical phosphoproteome of 8-week-old (prior to motor deficits) and 20-week-old (fully symptomatic) R6/1 transgenic HD mice. When comparing 8-week-old HD mice with their wild-type (WT) littermates, we found 660 peptides differentially phosphorylated, which were mapped to 227 phosphoproteins. These proteins were mainly involved in synaptogenesis, cytoskeleton organization, axon development, and nervous system development. Tau protein, found hyperphosphorylated at multiple sites in early symptomatic HD mice, also appeared as a main upstream regulator for the changes observed. Surprisingly, we found fewer changes in the phosphorylation profile of HD mice at the fully symptomatic stage, with 29 peptides differentially phosphorylated compared to WT mice, mapped to 25 phosphoproteins. These proteins were involved in cAMP signaling, dendrite development, and microtubule binding. Furthermore, huntingtin protein appeared as an upstream regulator for the changes observed at the fully symptomatic stage, suggesting impacts on kinases and phosphatases that extend beyond the mutated polyglutamine tract. In summary, our findings show that the most extensive changes in the phosphorylation machinery appear at an early presymptomatic stage in HD pathogenesis and might constitute a new target for the development of treatments.
- Published
- 2022
- Full Text
- View/download PDF
3. Optimizing red blood cell protein extraction for biomarker quantitation with mass spectrometry
- Author
-
Blaine R. Roberts, Christopher Fowler, Amber Lothian, Roberto Cappai, Anne M. Roberts, Stephan Klatt, and Colin L. Masters
- Subjects
Erythrocytes ,Lysis ,02 engineering and technology ,Proteomics ,01 natural sciences ,Biochemistry ,Mass Spectrometry ,Analytical Chemistry ,Freezing ,Protein purification ,medicine ,Humans ,Chromatography ,Chemistry ,010401 analytical chemistry ,Blood Proteins ,021001 nanoscience & nanotechnology ,Blood proteins ,High-Throughput Screening Assays ,0104 chemical sciences ,Red blood cell ,medicine.anatomical_structure ,Proteome ,alpha-Synuclein ,Biomarker (medicine) ,Hemoglobin ,0210 nano-technology ,Biomarkers ,Chromatography, Liquid - Abstract
Red blood cells (RBC) are the most common cell type found in blood. They might serve as reservoir for biomarker research as they are anuclear and lack the ability to synthesize proteins. Not many biomarker assays, however, have been conducted on RBC because of their large dynamic range of proteins, high abundance of lipids, and hemoglobin interferences. Here, we developed a semiquantitative mass spectrometry-based assay that targeted 144 proteins and compared the efficiency of urea, sodium deoxycholate, acetonitrile, and HemoVoid™ in their extraction of the RBC proteome. Our results indicate that protein extraction with HemoVoid™ led to hemoglobin reduction and increased detection of low abundance proteins. Although hemoglobin interference after deoxycholate and urea extraction was high, there were adequate amounts of low abundance proteins for quantitation. Extraction with acetonitrile led to an overall decrease in protein abundances probably as a result of precipitation. Overall, the best compromise in sensitivity and sample processing time was achieved with the urea-trypsin digestion protocol. This provided the basis for large-scale evaluations of protein targets as potential blood-based biomarkers. As a proof of concept, we applied this assay to determine that alpha-synuclein, a prominent marker in Parkinson's disease, has an average concentration of approximately 40 μg mL-1 in RBC. This is important to know as the concentration of alpha-synuclein in plasma, typically in the picogram per milliliter range, might be partially derived from lysed RBC. Utilization of this assay will prove useful for future biomarker studies and provide a more complete analytical toolbox for the measurement of blood-derived proteins. Graphical abstract.
- Published
- 2020
- Full Text
- View/download PDF
4. Glutathione peroxidase 4: a new player in neurodegeneration?
- Author
-
Blaine R. Roberts, Ashley I. Bush, Dominic J. Hare, and Bárbara Rita Cardoso
- Subjects
0301 basic medicine ,Programmed cell death ,Antioxidant ,medicine.medical_treatment ,GPX4 ,Selenium ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Selenium deficiency ,medicine ,Animals ,Humans ,Phospholipid-hydroperoxide glutathione peroxidase ,Molecular Biology ,chemistry.chemical_classification ,Glutathione Peroxidase ,Cell Death ,business.industry ,Glutathione peroxidase ,Neurodegeneration ,Neurodegenerative Diseases ,Phospholipid Hydroperoxide Glutathione Peroxidase ,medicine.disease ,Cell biology ,Psychiatry and Mental health ,030104 developmental biology ,chemistry ,Cancer cell ,business ,Neuroscience - Abstract
Glutathione peroxidase 4 (GPx4) is an antioxidant enzyme reported as an inhibitor of ferroptosis, a recently discovered non-apoptotic form of cell death. This pathway was initially described in cancer cells and has since been identified in hippocampal and renal cells. In this Perspective, we propose that inhibition of ferroptosis by GPx4 provides protective mechanisms against neurodegeneration. In addition, we suggest that selenium deficiency enhances susceptibility to ferroptotic processes, as well as other programmed cell death pathways due to a reduction in GPx4 activity. We review recent studies of GPx4 with an emphasis on neuronal protection, and discuss the relevance of selenium levels on its enzymatic activity.
- Published
- 2016
- Full Text
- View/download PDF
5. CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord
- Author
-
James B. Hilton, Nastasia K. H. Lim, Peter J. Crouch, Blaine R. Roberts, Anthony R. White, Stephen W. Mercer, Gojko Buncic, Noel G. Faux, Paul S. Donnelly, and Joseph S. Beckman
- Subjects
0301 basic medicine ,Genetically modified mouse ,Multidisciplinary ,Transgene ,Central nervous system ,SOD1 ,Wild type ,nutritional and metabolic diseases ,Biology ,medicine.disease ,Spinal cord ,3. Good health ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Gliosis ,Immunology ,medicine ,Cancer research ,Amyotrophic lateral sclerosis ,medicine.symptom ,030217 neurology & neurosurgery - Abstract
Ubiquitous expression of mutant Cu/Zn-superoxide dismutase (SOD1) selectively affects motor neurons in the central nervous system (CNS), causing the adult-onset degenerative disease amyotrophic lateral sclerosis (ALS). The CNS-specific impact of ubiquitous mutant SOD1 expression is recapitulated in transgenic mouse models of the disease. Here we present outcomes for the metallo-complex CuII(atsm) tested for therapeutic efficacy in mice expressing SOD1G93A on a mixed genetic background. Oral administration of CuII(atsm) delayed the onset of neurological symptoms, improved locomotive capacity and extended overall survival. Although the ALS-like phenotype of SOD1G93A mice is instigated by expression of the mutant SOD1, we show the improved phenotype of the CuII(atsm)-treated animals involves an increase in mature mutant SOD1 protein in the disease-affected spinal cord, where concomitant increases in copper and SOD1 activity are also evident. In contrast to these effects in the spinal cord, treating with CuII(atsm) had no effect in liver on either mutant SOD1 protein levels or its activity, indicating a CNS-selective SOD1 response to the drug. These data provide support for CuII(atsm) as a treatment option for ALS as well as insight to the CNS-selective effects of mutant SOD1.
- Published
- 2017
- Full Text
- View/download PDF
6. The prion protein regulates beta-amyloid-mediated self-renewal of neural stem cells in vitro
- Author
-
Victoria Lewis, Blaine R. Roberts, Steven J. Collins, Cathryn L. Haigh, Victoria A. Lawson, Qiao-Xin Li, Timothy M. Ryan, Carolin Tumpach, and Simon C. Drew
- Subjects
Amyloid ,Prions ,Neurogenesis ,animal diseases ,Short Report ,Medicine (miscellaneous) ,Subventricular zone ,Biology ,Biochemistry, Genetics and Molecular Biology (miscellaneous) ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Neural Stem Cells ,medicine ,Animals ,reproductive and urinary physiology ,Cell Proliferation ,030304 developmental biology ,0303 health sciences ,Amyloid beta-Peptides ,Cell growth ,Neurodegeneration ,Cell Cycle Checkpoints ,Cell Biology ,medicine.disease ,Neural stem cell ,Mitochondria ,nervous system diseases ,Cell biology ,medicine.anatomical_structure ,Microscopy, Fluorescence ,nervous system ,Molecular Medicine ,biological phenomena, cell phenomena, and immunity ,Stem cell ,Signal transduction ,030217 neurology & neurosurgery ,Signal Transduction - Abstract
The beta-amyloid (Aβ) peptide and the Aβ-oligomer receptor, prion protein (PrP), both influence neurogenesis. Using in vitro murine neural stem cells (NSCs), we investigated whether Aβ and PrP interact to modify neurogenesis. Aβ imparted PrP-dependent changes on NSC self-renewal, with PrP-ablated and wild-type NSCs displaying increased and decreased cell growth, respectively. In contrast, differentiation of Aβ-treated NSCs into mature cells was unaffected by PrP expression. Such marked PrP-dependent differences in NSC growth responses to Aβ provides further evidence of biologically significant interactions between these two factors and an important new insight into regulation of NSC self-renewal in vivo. Electronic supplementary material The online version of this article (doi:10.1186/s13287-015-0067-4) contains supplementary material, which is available to authorized users.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.